Jim has more than 25 years of experience in biopharma investing. He leverages our science expertise to identify trends and find new investment opportunities. He led the research and investments team from 2008 to 2020. Prior to joining Royalty Pharma in 2008, Jim led healthcare research at FBR Capital Markets. Previously, Jim was a biotechnology analyst at Bank of America and CIBC World Markets. Jim serves on the national board of the Leukemia and Lymphoma Society (LLS), the board of Avillion, a London-based drug development company, and on Memorial Sloan Kettering Cancer Center’s external review board for its Technology Development Fund. Jim has a BA from Furman University, a PhD in biochemistry and molecular genetics from the UAB, and was a postdoctoral fellow at Yale University.